Company / Revenue
CRISPR Therapeutics AG Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$3.5M
FY2025
5-year range
$1.2M / $915.0M
FY2021-FY2025
Trend
-90.6%
vs FY2024
Sector context
#140 of 153
Health Care
What the data says
Among 153 Health Care companies, CRISPR Therapeutics AG is in the bottom 8% for revenue. Revenue has fluctuated over the past 10 years, ranging from $328,000 in FY2019 to $915M in FY2021.
Based on SEC 10-K filings.
$4M in FY2025 with a 5-year CAGR of +37.3%.
Declined from $371M to $4M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +43.1%
- 5-Year CAGR
- +37.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 153This company $3.5M Sector average $4.5B
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +37.3%, indicating consistent growth.
- In FY2025, revenue decreased 90.6% year-over-year.
- Ranks #140 out of 153 companies in the Health Care sector.
- Peak revenue was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.5M | -90.6% |
| FY2024 | $37.3M | -89.9% |
| FY2023 | $371.2M | +30885.5% |
| FY2022 | $1.2M | -99.9% |
| FY2021 | $915.0M | +127154.9% |
| FY2020 | $719.0K | +119.2% |
| FY2019 | $328.0K | -89.5% |
| FY2018 | $3.1M | -92.4% |
| FY2017 | $41.0M | +693.9% |
| FY2016 | $5.2M | +1990.7% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026